Escitalopram side effects: what 139,448 FDA adverse event reports show
Drug class
Selective serotonin reuptake inhibitor (ssri)
Brand names
Escitalopram Oxalate
Who reports
139,448 reports · 67% serious · 11,263 with death outcome · 69% female
Used for
Escitalopram oral solution is indicated for the treatment of: major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. generalized anxiety disorder (GAD) in adults. Additional pediatric use information is approved for AbbVie Inc.’s LEXAPRO (escitalopram) oral solution.
What it is
Escitalopram is a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre.
Boxed warning
SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] .
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,123 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Spirometry abnormal | 288 | 145.3 123.5–171.0ROR 145.6 · calibrated p 7e-9 ✓ | 73.3 EB05 66.5 · IC025 +5.8 3/3 methods agree | Lab value / disease marker | serious n=288 · ♀ 0% (drug 69%) | no trial arm names this drug |
| Mite allergy | 274 | 113.4 96.9–132.7ROR 113.6 · calibrated p 5e-8 ✓ | 64.2 EB05 58.1 · IC025 +5.7 3/3 methods agree | Labeled (related wording) related wording | serious n=273 · ♀ 0% (drug 69%) | no trial arm names this drug |
| Total lung capacity abnormal | 133 | 80.6 65.3–99.6ROR 80.7 · calibrated p 7e-7 ✓ | 52.1 EB05 45.1 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=132 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Mycotic allergy | 274 | 72.3 62.6–83.6ROR 72.5 · calibrated p 1e-6 ✓ | 48.7 EB05 44.0 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=271 · ♀ 0% (drug 69%) | no trial arm names this drug |
| Pulmonary vasculitis | 155 | 62.2 51.6–75.1ROR 62.3 · calibrated p 4e-6 ✓ | 43.8 EB05 38.3 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=155 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Dust allergy | 275 | 59.8 52.0–68.8ROR 60.0 · calibrated p 5e-6 ✓ | 42.7 EB05 38.7 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=272 · ♀ 0% (drug 69%) | no trial arm names this drug |
| Amaurosis fugax | 243 | 44.0 38.2–50.8ROR 44.1 · calibrated p 3e-5 ✓ | 34.1 EB05 30.6 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=243 · 100% clinician | no trial arm names this drug |
| Vital capacity decreased | 101 | 43.3 34.7–54.0ROR 43.3 · calibrated p 4e-5 ✓ | 33.5 EB05 28.3 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=101 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Conjunctivitis allergic | 295 | 37.8 33.3–43.0ROR 37.9 · calibrated p 8e-5 ✓ | 30.3 EB05 27.5 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=293 · ♀ 0% (drug 69%) | no trial arm names this drug |
| Reversible airways obstruction | 102 | 37.0 29.8–46.0ROR 37.0 · calibrated p 1e-4 ✓ | 29.6 EB05 25.1 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=102 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Steroid dependence | 167 | 36.6 30.9–43.4ROR 36.7 · calibrated p 1e-4 ✓ | 29.4 EB05 25.9 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=167 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Catarrh | 153 | 31.1 26.1–37.0ROR 31.1 · calibrated p 2e-4 ✓ | 25.8 EB05 22.5 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=153 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Antineutrophil cytoplasmic antibody positive | 105 | 25.2 20.5–31.0ROR 25.2 · calibrated p 7e-4 ✓ | 21.6 EB05 18.3 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=105 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Sputum culture positive | 106 | 22.1 18.0–27.1ROR 22.1 · calibrated p 0.001 ✓ | 19.3 EB05 16.4 · IC025 +3.8 3/3 methods agree | Lab value / disease marker | serious n=105 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Physical deconditioning | 303 | 20.6 18.3–23.2ROR 20.6 · calibrated p 0.002 ✓ | 18.2 EB05 16.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=301 | no trial arm names this drug |
| Neuritis | 163 | 17.7 15.1–20.8ROR 17.7 · calibrated p 0.004 ✓ | 15.9 EB05 13.9 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=161 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Normochromic normocytic anaemia | 302 | 16.7 14.8–18.8ROR 16.8 · calibrated p 0.004 ✓ | 15.1 EB05 13.7 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=302 · ♀ 0% (drug 69%) | no trial arm names this drug |
| Burns second degree | 171 | 16.2 13.8–19.0ROR 16.2 · calibrated p 0.005 ✓ | 14.6 EB05 12.9 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=170 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Bronchial secretion retention | 117 | 15.2 12.6–18.4ROR 15.3 · calibrated p 0.007 ✓ | 13.8 EB05 11.8 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | serious n=117 · ♀ 100% (drug 69%) | no trial arm names this drug |
| Serotonin syndrome | 1,668 | 14.3 13.6–15.0ROR 14.4 · calibrated p 0.008 ✓ | 13.1 EB05 12.6 · IC025 +3.6 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 9.5 · serious PRR 11.2 | no trial arm names this drug |
| Major depression | 630 | 14.1 13.0–15.3ROR 14.1 · calibrated p 0.009 ✓ | 12.9 EB05 12.1 · IC025 +3.5 3/3 methods agree | Labeled (related wording) related wording | serious PRR 11.3 | no trial arm names this drug |
| Reversible cerebral vasoconstriction syndrome | 168 | 14.0 11.9–16.4ROR 14.0 · calibrated p 0.010 ✓ | 12.8 EB05 11.2 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=168 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Eosinophilic granulomatosis with polyangiitis | 160 | 12.9 10.9–15.1ROR 12.9 · calibrated p 0.013 ✓ | 11.8 EB05 10.3 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=160 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Sleep talking | 113 | 10.6 8.7–12.8ROR 10.6 · calibrated p 0.028 ✓ | 9.8 EB05 8.3 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=91 · ♀ 0% (drug 69%) · 100% consumer | no trial arm names this drug |
| Alcohol poisoning | 160 | 9.6 8.2–11.2ROR 9.6 · calibrated p 0.038 ✓ | 8.9 EB05 7.8 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=156 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Respiratory symptom | 167 | 9.5 8.1–11.1ROR 9.5 · calibrated p 0.040 ✓ | 8.8 EB05 7.7 · IC025 +2.9 3/3 methods agree | Labeled (related wording) related wording | serious n=165 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Anorgasmia | 158 | 9.2 7.8–10.8ROR 9.2 · calibrated p 0.044 ✓ | 8.6 EB05 7.5 · IC025 +2.8 3/3 methods agree | Labeled adverse reaction exact term | serious n=120 · ♀ 44% (drug 69%) · 100% consumer | no trial arm names this drug |
| Gun shot wound | 109 | 9.1 7.5–11.0ROR 9.1 · calibrated p 0.046 ✓ | 8.4 EB05 7.2 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=107 · ♀ 0% (drug 69%) · 100% consumer | no trial arm names this drug |
| Hypopnoea | 193 | 8.8 7.6–10.2ROR 8.8 · calibrated p 0.050 ✓ | 8.3 EB05 7.3 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=184 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Urinary tract disorder | 249 | 8.8 7.7–9.9ROR 8.8 · calibrated p 0.051 | 8.2 EB05 7.4 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | serious n=241 · 100% clinician | no trial arm names this drug |
| Electric shock sensation | 145 | 8.5 7.2–10.1ROR 8.5 · calibrated p 0.056 | 8.0 EB05 6.9 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | serious n=126 · 100% consumer | no trial arm names this drug |
| Clonus | 145 | 8.3 7.1–9.9ROR 8.3 · calibrated p 0.060 | 7.8 EB05 6.8 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | serious n=144 · 100% clinician | no trial arm names this drug |
| Forced expiratory volume decreased | 145 | 8.0 6.8–9.5ROR 8.1 · calibrated p 0.067 | 7.5 EB05 6.6 · IC025 +2.6 3/3 methods agree | Lab value / disease marker | serious n=144 · ♀ 0% (drug 69%) · 100% clinician | no trial arm names this drug |
| Sleep terror | 208 | 7.8 6.8–8.9ROR 7.8 · calibrated p 0.074 | 7.3 EB05 6.5 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=186 · ♀ 0% (drug 69%) | no trial arm names this drug |
| Hyperreflexia | 171 | 7.7 6.6–8.9ROR 7.7 · calibrated p 0.077 | 7.2 EB05 6.4 · IC025 +2.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=166 · 100% clinician | no trial arm names this drug |
| Hyperparathyroidism secondary | 123 | 7.6 6.4–9.1ROR 7.6 · calibrated p 0.079 | 7.1 EB05 6.1 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=123 | no trial arm names this drug |
| Sexual dysfunction | 558 | 7.5 6.9–8.2ROR 7.5 · calibrated p 0.080 | 7.1 EB05 6.7 · IC025 +2.7 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 7.4 · ♀ 35% (drug 69%) · 71% consumer | no trial arm names this drug |
| Nephrogenic anaemia | 219 | 7.3 6.4–8.4ROR 7.4 · calibrated p 0.087 | 7.0 EB05 6.2 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=219 | no trial arm names this drug |
| Depressive symptom | 162 | 7.2 6.2–8.5ROR 7.2 · calibrated p 0.092 | 6.8 EB05 6.0 · IC025 +2.5 3/3 methods agree | Labeled (related wording) related wording | serious n=142 | no trial arm names this drug |
| Haemorrhagic stroke | 355 | 7.1 6.4–7.9ROR 7.1 · calibrated p 0.096 | 6.7 EB05 6.2 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious PRR 5.8 · ♀ 0% (drug 69%) | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Suicidality | 8,107 | 5.15.0–5.2 | signal |
| Depression | 7,568 | 4.14.0–4.2 | signal |
| Extrapyramidal | 2,361 | 3.43.3–3.6 | signal |
| Hyponatraemia | 1,768 | 3.43.2–3.5 | signal |
| Fall / fracture | 5,841 | 2.32.3–2.4 | signal |
| Arrhythmia / qt | 2,870 | 2.22.2–2.3 | signal |
| Seizure | 2,630 | 2.02.0–2.1 | raised |
| Venous thromboembolism | 2,883 | 2.01.9–2.1 | raised |
| Rhabdomyolysis / myopathy | 933 | 1.71.6–1.9 | raised |
| Pancreatitis | 925 | 1.71.6–1.8 | raised |
| Gi bleeding | 1,990 | 1.61.6–1.7 | raised |
| Serious infection | 7,239 | 1.41.4–1.4 | raised |
| Kidney injury | 4,192 | 1.41.3–1.4 | raised |
| Anaemia | 2,722 | 1.41.3–1.4 | raised |
| Stroke | 2,246 | 1.41.3–1.4 | raised |
| Hyperglycaemia / diabetes | 3,092 | 1.31.3–1.4 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Fatigue (tiredness) | 9,543 | 1.9 1.8–1.9ROR 1.9 · calibrated p 0.900 | 1.8 EB05 1.8 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.8 | no trial arm names this drug |
| Nausea | 9,518 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.879 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.9 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 8,996 | 1.0 1.0–1.0ROR 1.0 · calibrated p 0.325 | 1.0 EB05 1.0 · IC025 +0.0 | Reporting / coding artifact | age-adj. PRR 1.1 · serious PRR 1.4 | no trial arm names this drug |
| Headache | 7,397 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.847 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 2.0 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 7,045 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.762 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.6 | no trial arm names this drug |
| Anxiety | 6,668 | 3.6 3.5–3.7ROR 3.7 · calibrated p 0.437 | 3.5 EB05 3.4 · IC025 +1.8 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 3.4 · serious PRR 3.4 | no trial arm names this drug |
| Dizziness | 6,311 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.922 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.0 | no trial arm names this drug |
| Off label use (used outside approved label) | 6,208 | 1.1 1.0–1.1ROR 1.1 · calibrated p 0.359 | 1.1 EB05 1.1 · IC025 +0.1 | Reporting / coding artifact | age-adj. PRR 1.0 · serious PRR 1.2 | no trial arm names this drug |
| Depression | 6,155 | 4.1 4.0–4.2ROR 4.3 · calibrated p 0.329 | 4.0 EB05 4.0 · IC025 +2.0 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 3.7 · serious PRR 3.8 | no trial arm names this drug |
| Pain | 5,821 | 1.4 1.4–1.5ROR 1.4 · calibrated p 0.605 | 1.4 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.4 | no trial arm names this drug |
| Fall | 5,577 | 2.5 2.5–2.6ROR 2.6 · calibrated p 0.766 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 2.2 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 5,493 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.631 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.4 | no trial arm names this drug |
| Vomiting | 5,301 | 1.7 1.7–1.8ROR 1.7 · calibrated p 0.791 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.7 | no trial arm names this drug |
| Insomnia (trouble sleeping) | 4,491 | 2.6 2.5–2.6ROR 2.6 · calibrated p 0.768 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 2.7 | no trial arm names this drug |
| Asthenia (weakness) | 4,457 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.840 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.7 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Total lung capacity abnormal — n=133, PRR 80.6
- Mycotic allergy — n=274, PRR 72.3
- Pulmonary vasculitis — n=155, PRR 62.2
- Dust allergy — n=275, PRR 59.8
- Amaurosis fugax — n=243, PRR 44.0
- Vital capacity decreased — n=101, PRR 43.3
- Conjunctivitis allergic — n=295, PRR 37.8
- Reversible airways obstruction — n=102, PRR 37.0
- Steroid dependence — n=167, PRR 36.6
- Catarrh — n=153, PRR 31.1
✓ A hand-written Bradford Hill causality assessment exists for this drug: Escitalopram ↔ QT prolongation.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Escitalopram?
In FDA FAERS, the most frequently co-reported reaction terms for Escitalopram are fatigue, nausea, headache, diarrhoea, anxiety, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Escitalopram have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] .
Do FAERS signals prove that Escitalopram causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 09894a38-4e3a-475d-96cd-c6c8ed87869a, effective 20250422; matched on
openfda.generic_name.exact:"ESCITALOPRAM" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 146570 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,163 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ESCITALOPRAM, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.